Form 4: Neurocrine Biosciences Director Reports Stock Transactions

Director Leslie V. Norwalk reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Summary

• On May 22, 2025, Leslie V. Norwalk, a director of Neurocrine Biosciences Inc., reported transactions involving the company's stock.
• Norwalk acquired 1,659 Restricted Stock Units (RSUs) on May 21, 2025, which will vest fully on May 21, 2026.
• Norwalk also acquired 3,305 Non-Qualified Stock Options on May 21, 2025, vesting in 12 monthly installments beginning June 21, 2025, and expiring on May 21, 2035.
• Additionally, Norwalk disposed of 1,435 shares of common stock on May 22, 2025.
• Following these transactions, Norwalk directly owns 0 shares of common stock and 3,305 derivative securities.
• Norwalk also disposed of 1,435 Restricted Stock Units (RSUs) on May 22, 2025, which were granted on May 22, 2024 and fully vested.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting transactions. The sentiment depends on how investors interpret the director's actions (acquiring vs. disposing of shares).

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 1,435 shares of common stock by a director could be interpreted negatively by some investors.

Risks

• The value of the stock options is dependent on the future performance of Neurocrine Biosciences' stock.
• Vesting schedules mean the director's incentives are aligned with the long-term performance of the company, but also introduce a time element to consider.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a long-term alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and expectations for the company's future.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices for directors in the biotechnology industry, aligning their interests with shareholder value creation.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their directors.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions reflect the compensation structure for the company's directors.

Key Dates

Keywords

Neurocrine Biosciences, Director, Stock Options, RSU, Form 4, NBIX, Securities, Transactions